60

RUJUKAN
1. WHO/CDC/ICBDSR. Birth defects surveillance: atlas of selected congenital anomalies.
Geneva: World Health Organization; 2014.
2. WHO. Prevention and Control of Birth Defects in South-East Asia Region. India: World
Health Organization; 2013.
3. Christianson A, Howson CP, Modell B. March of dimes: global report on birth defects.
New York: White Plains; 2006.
4. Kebijakan surveilans kelainan kongenital di indonesia. Lukas C Hermawan. Jakarta 25
juli. Direktorat kesehatan keluarga. Kemenkes RI
5. Cohen HL, Kravets F, Zucconi W, Ratani R, Shah S, Dougherty D. Congenital
Abnormalities of the Genitourinary System. Seminars in Roentgenology. 2004;39(2):282-
303. Diunduh dari : Science Direct
6. Fernandez N, Henao-Mejia J, Monterrey P, Perez J, Zarante. Association between
Maternal Prenatal Vitamin Use and Congenital Abnormalities of The Genitourinary Tract
in A Developing Country. Journal of Pediatric Urology. 2011 (disitasi: 10 Desember
2012); 7(5):121-26. Diunduh dari :
http://www.sciencedirect.com/science/article/pii/S1477513111001781
7. Tseng JJ, Ping Ho JY, Chen WH, Chou MM. Prenatal Diagnosis of Isolated Fetal
Hydrocolpos Secondary to Congenital Imperforate Hymen. Journal of the Chinese
Medical Association. 2008 ;71 (6):325-8. Diunduh dari : Science Direct
8. Sipek A, Congenital anomalies: Etiology, diagnosis, and incidence. Department of
Medical Genetics Thomayer Faculty Hospital.
9. Effendi SH, Penanganan bayi dengan kelainan kongenital dan konseling genetik.
Simposium Building Golden generation. Universitas Padjajaran. Bandung. 2014
10. Surya IGPS, Negara KS, Roeswadi RH, dkk. Panduan Pengelolan Kelainan Bawaan di
Indonesia, Edisi I. Himpunan Kedokteran Fetomaternal. 2006.
11. Cunningham FG, Leveno KJ, Bloom SL, Spong YS, Dashe JS. Hoffman BL, et al,
editors. Embryogenesis and fetal morphological development. In: Williams Obstetrics.
24th ed. United States (US): McGraw-Hill Education;2014
12. Van Gelder dkk, Teratogenic mechanisms of medical drugs. Human Reproduction
Update, Vol.16, No.4 pp. 378–394, 2010
13. Brouwer IA, van Dusseldorp M, West CE, Meyboom S, Thomas CMG, uran M, van het
Hof KH, Eskes TKAB, Hautvast JGAJ, Steegers-Theunissen RPM. Dietary folate from
vegetables and citrus fruit decreases plasma homocysteine concentrations in humans in a
dietary controlled trial. J Nutr 1999;129:1135–1139.
14. Antony AC. The biological chemistry of folate receptors. Blood 1992; 79:2807–2820.
15. van der Put NMJ, van Straaten HWM, Trijbels FJM, Blom HJ. Folate, homocysteine and
neural tube defects: an overview. Exp Biol Med 2001;226:243–270.
16. Lambie DG, Johnson RH. Drugs and folate metabolism. Drugs 1985; 30:145–155.
17. Li D, Pickell L, Liu Y, Wu Q, Cohn JS, Rozen R. Maternal methylenetetrahydrofolate
reductase deficiency and low dietary folate lead to adverse reproductive outcomes and
congenital heart defects in mice. Am J Clin Nutr 2005;82:188–195.
18. Lumley J, Watson L, Watson M, Bower C. Periconceptional supplementation with folate
and/or multivitamins for preventing neural tube defects. Cochrane Database Syst Rev
2001; doi:10.1002/ 14651858.CD001056.
19. Candito M, Rivet R, Herbeth B, Boisson C, Rudigoz RC, Luton D, et al. Nutritional and
genetic determinants of vitamin B and homocysteine metabolisms in neural tube defects:
a multicenter case–control study. Am J Med Genet A 2008;146:1128–1133.
20. Zhang HY, Luo GA, Liang QL, Wang Y, Yang HH, Wang YM, et al. Neural tube defects
and disturbed maternal folate- and homocysteine-mediated one-carbon metabolism. Exp
Neurol 2008;212:515–521.
21. van Rooij IALM, Ocke´ MC, Straatman H, Zielhuis GA, Merkus HMWM, Steegers-
Theunissen RPM. Periconceptional folate intake by supplement and food reduces the risk
of nonsyndromic cleft lip with or without cleft palate. Prev Med 2004;39:689–694.
22. Wilcox AJ, Lie RT, Solvoll K, Taylor J, McConnaughey DR, A˚ byholm F, Vindenes H,
Vollset SE, Drevon CA. Folic acid supplements and risk of facial clefts: national
population based case–control study. Br Med J 2007;334:464.
 61

23. Werler MM, Hayes C, Louik C, Shapiro S, Mitchell AA. Multivitamin supplementation
and risk of birth defects. Am J Epidemiol 1999; 150:675–682.
24. Sahambi SK, Hales BF. Exposure to 5-bromo-2’-deoxyuridine induces oxidative stress
and activator protein-1 DNA binding activity in the embryo. Birth Defects Res A Clin
Mol Teratol 2006;76:580–591.
25. Zaken V, Kohen R, Ornoy A. The development of antioxidant defense mechanism in
young rat embryos in vivo and in vitro. Early Pregnancy 2000;4:110–123.
26. Foster W, Myllynen P, Winn LM, Ornoy A, Miller RK. Reactive oxygen species,
diabetes and toxicity in the placenta: a workshop report. Placenta 2008;29:S105–S107.
27. Yan J, Hales BF. Depletion of glutathione induces 4-hydroxynonenal protein adducts and
hydroxyurea teratogenicity in the organogenesis stage mouse embryo. J Pharmacol Exp
Ther 2006; 319:613–621.
28. Nielsen GL, Sørensen HT, Larsen H, Pedersen L. Risk of adverse birth outcome and
miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: population based
observational study and case–control study. Br Med J 2001;322:266–270.
29. Cleves MA, Savell VH Jr, Raj S, Zhao W, Correa A, Werler MM, Hobbs CA. Maternal
use of acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs), and muscular
ventricular septal defects. Birth Defects Res A Clin Mol Teratol 2004;70:107–113.
30. Ka¨lle´n BAJ, Otterblad Olausson P. Maternal use of selective serotonin re-uptake
inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A
Clin Mol Teratol 2007;79:301–308.
31. Hagiwara N, Katarova Z, Siracusa LD, Brilliant MH. Nonneuronal expression of the
GABAA ß3 subunit gene is required for normal palate development in mice. Dev Biol
2003;254:93–101
32. Lin AE, Peller AJ, Westgate MN, Houde K, Franz A, Holmes LB. Clonazepam use in
pregnancy and the risk of malformations. Birth Defects Res A Clin Mol Teratol
2004;70:534–536.
33. Goetzinger K, Shanks A, Odibo A, Macones G, Cahill A. Advanced maternal age and the
risk of major congenital anomalies: survival of the fittest?. AJOG. 2014.
34. Lindbohm ML, Sallmen M. Reproductive effects caused by chemical and biological
agents. Finnish Institute of Occupational Health.
35. Woods SE, Raju U. Maternal smoking and the risk of congenital birth defecrts: a cohort
study. (J Am Board Fam Pract 2001;14:330–4.)
36. Supono. Patogenesis Kelainan Fetus dan Neonatus. 2017
37. Marengo L, Farag NH, Canfield M. Body mass index and birth defects: Texas, 2005-
2008. Matern Child Health J 2013 Dec;17(10):1898-1907.
38. Block SR, Watkins SM, Salemi JL, Rutkowski R, Tanner JP, Correia JA, et al. Maternal
prepregnancy body mass index and risk of selected birth defects: evidence of a dose-
response relationship. Paediatr Perinat Epidemiol 2013 Nov;27(6):521-531.
39. Aune D, Saugstad OD, Henriksen T, Tonstad S. Maternal body mass index and the risk of
fetal death, stillbirth, and infant death: a systematic review and meta-analysis. JAMA
2014 Apr 16;311(15):1536-1546.
40. Flenady V, Koopmans L, Middleton P, Froen JF, Smith GC, Gibbons K, et al. Major risk
factors for stillbirth in high-income countries: a systematic review and meta-analysis.
Lancet 2011 Apr 16;377(9774):1331-1340.
41. Taboo, Z. (2012): Prevalence and risk factors for congenital anomalies in Mosul City.
The Iraqi Postgraduate Medical Journal; 11 (2), 458-470.
42. Othman, G. (2013): The Prevalence and types of congenital anomalies in newborn in
Erbel, Iraq. Medical Journal of Islamic World Academy of Sciences; 21(1), 31-34.
43. Tayebi, N., Yazdani, K. &Naghshin, N. (2010): The prevalence of congenital
malformations and its correlation with consanguineous marriages. Oman Medical
Journal; 25 (1), 37-40.
44. Sullivan, S. (2010): Birth defects and the maternal diet. Available at
www.everydayhealth.com, accessed at 20/8/2013.
45. Ward-Platt M, Stevens S, Miller N. I18 The national congenital anomaly and rare disease
registration service (ncardrs): the first year. BMJ Publishing Group Ltd; 2018.
46. Leung S, Utz M, Johnston T. Morbidity and mortality associated with older maternal age
at birth, Queensland, 2014 and 2015. 2018;
 62

47. Honkaniemi H. 8th European Public Health Conference: Poster Walks 309.
2013;(January):309.
48. Taruscio D, Baldi F, Carbone P, Neville AJ, Rezza G, Rizzo C, et al. Primary Prevention
of Congenital Anomalies: Special Focus on Environmental Chemicals and other
Toxicants, Maternal Health and Health Services and Infectious Diseases. In: Rare
Diseases Epidemiology: Update and Overview. Springer; 2017. p. 301–22.
49. Duong HT, Hoyt AT, Carmichael SL, Gilboa SM, Mark A, Case A, et al. HHS Public
Access. 2015;94(4):230–6.
50. Baldacci S, Gorini F, Santoro M, Pierini A, Minichilli F, Bianchi F. Environmental and
individual exposure and the risk of congenital anomalies: a review of recent
epidemiological evidence. Epidemiol Prev. 2018;42(3–4S1):1–34.
51. Gong W, Liang Q, Zheng D, Zhong R, Wen Y, Wang X. Congenital heart defects of fetus
after maternal exposure to organic and inorganic environmental factors: a cohort study.
Oncotarget. 2017;8(59):100717.
52. Sheridan E, Wright J, Small N, Corry PC, Oddie S, Whibley C, et al. Risk factors for
congenital anomaly in a multiethnic birth cohort: an analysis of the Born in Bradford
study. Lancet. 2013;382(9901):1350–9.
53. Glinianaia S V, Tennant PWG, Rankin J. Risk estimates of recurrent congenital
anomalies in the UK: a population-based register study. BMC Med. 2017;15(1):20.
54. Tayebi N, Yazdani K, Naghshin N. The Prevalence of Congenital Malformations and its
Correlation with Consanguineous Marriages. Oman Med J [Internet]. 2010;25(1):37–40.
Available from:
http://www.omjournal.org/OriginalArticles/FullText/201001/FT_ThePrevalence
ofCongenitalMalformations.html
55. Schmitz-Feuerhake I, Busby C, Pflugbeil S. Genetic radiation risks: a neglected topic in
the low dose debate. Environ Health Toxicol. 2016;31.
56. Ban L, West J, Gibson JE, Fiaschi L, Sokal R, Doyle P, et al. First trimester exposure to
anxiolytic and hypnotic drugs and the risks of major congenital anomalies: a United
Kingdom population-based cohort study. PLoS One. 2014;9(6):e100996.
57. Weller A, Daniel S, Koren G, Lunenfeld E, Levy A. The fetal safety of clomiphene
citrate: a population‐based retrospective cohort study. BJOG An Int J Obstet Gynaecol.
2017;124(11):1664–70.
58. Wilson RD, Audibert F, Brock J-A, Carroll J, Cartier L, Gagnon A, et al. Pre-conception
folic acid and multivitamin supplementation for the primary and secondary prevention of
neural tube defects and other folic acid-sensitive congenital anomalies. J Obstet Gynaecol
Canada. 2015;37(6):534–49
59. De‐Regil LM, Peña‐Rosas JP, Fernández‐Gaxiola AC, Rayco‐Solon P. Effects and safety
of periconceptional oral folate supplementation for preventing birth defects. Cochrane
Database Syst Rev. 2015;(12)
60. Carmichael SL, Shaw GM. Maternal corticosteroid use and risk of selected congenital
anomalies. Am J Med Genet. 1999;86(3)
61. Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW, García FAR, et
al. Folic acid supplementation for the prevention of neural tube defects: US Preventive
Services Task Force recommendation statement. Jama. 2017;317(2):183–9.